- Projects & figures
- News & Events
- Managing your project
- About ERC
The deep seafloor covers around 70% of our planet’s surface and is home to a diverse community of microorganisms, mostly bacteria. These single-cell life forms inhabit some of the most extreme places in the world, with freezing waters, permanent darkness, high pressure and little food. ERC grantee Antje Boetius studies these microbes in the abyss and their important role for the Earth’s nutrient cycles.
Effective treatment for obesity remains a challenge and the only intervention proven to maintain weight loss is bariatric surgery. Intrigued by the beneficial effect that this procedure has on the composition of gut microbiota, Dr Fredrik Bäckhed explores the possibility of mimicking these changes to develop a treatment for obesity that won’t require going under the knife.
The increasing development of wearable technology sparks the need for new, innovative ways to interact with our shiny gadgets. Deviating from the conventional approach based on touch-sensitive devices, Prof. Jürgen Steimle aims at producing body-worn user interfaces that can be applied directly on the skin. Highly personalised, biocompatible and ultrathin, these devices will seamlessly blend with the human skin to create a technological extension of our body.
Applied theatre tells a story not for the purposes of entertainment but for social, economic, political or therapeutic reasons. Prof. Matthias Warstat, funded by the ERC, wants to know more about the growth and impact of this form of theatre across the world.
CRISPR is a widely used molecular biology tool exploiting an immune process discovered in bacteria. Dr David Bikard studies CRISPR in bacterial cells, in conjunction with different DNA repair systems, to create even newer tools. He hopes to gain insight into bacterial genetics, and develop increasingly effective medical treatments.
For the first time ever, a team of scientists and clinicians led by the EU-funded researcher Mickael Tanter has managed to record the brain activity of a premature new-born baby during resting and during an epileptic seizure. Using a non-invasive ultrasound technology, this world premiere is a real game changer for researchers and the medical profession, offering a massive range of applications in neuroimaging and beyond. It is published today in Science Translational Medicine.
Pour la toute première fois, une équipe de scientifiques et des cliniciens dirigée par le chercheur Mickael Tanter, financé par l'UE, a réussi à enregistrer l'activité cérébrale d'un nouveau-né prématuré en phase de repos et lors d'une crise d'épilepsie. À l'aide d'une technologie d'échographie non invasive, cette première mondiale marque un véritable tournant dans le domaine de la recherche et la pratique médicale. Elle offre par ailleurs une vaste gamme d'applications en neuroimagerie et au-delà. L'étude est publiée aujourd'hui dans Science Translational Medicine.
Headscarves, mosques and halal shops — many EU citizens are Muslims, but visible signs of their faith are often viewed with distrust. What some Europeans see as a right to express their identity, others regard as a threat to societal core values. Insights from ERC-funded research into emblematic controversies may help to find a way forward.
Ole Kamstrup, MD., MSc., is a pensioner and lives north of Copenhagen in Denmark. He has been diagnosed with Parkinson's disease ten years ago. Since 2013, Mr Kamstrup has been in contact with Professor Deniz Kirik, a neuroscientist at Lund University in Sweden. Professor Kirik, who was awarded an ERC Starting Grant in 2009, develops new therapies for Parkinson’s disease, using viral vectors to deliver therapeutic genes to the brain. An ERC Proof of Concept grant enabled him to start carrying out a market evaluation and writing a business plan for the promising therapy.
Originally published in March 2017 as part of the multimedia campaign "ERC - 10 years – 10 portraits."
Cardiovascular diseases (CVD) are a major cause of morbidity and mortality in Europe. Prevention relies on measuring traditional risk factors such as age, gender, hypertension, diabetes, hypercholesterolemia and smoking. However, many individuals, apparently at low-risk, still develop CVD. Improving predictions beyond the traditional risk factors is the challenge undertaken by Prof. Olle Melander.